ResMed Price Target, Predictions & Analyst Ratings

+4.50 (+1.73 %)
(As of 07/27/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume502,134 shs
Average Volume630,553 shs
Market Capitalization$38.45 billion
P/E Ratio84.42
Dividend Yield0.60%

ResMed (NYSE:RMD) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
14 Wall Street analysts have issued ratings and price targets for ResMed in the last 12 months. Their average twelve-month price target is $241.50, predicting that the stock has a possible downside of 8.61%. The high price target for RMD is $270.00 and the low price target for RMD is $210.00. There are currently 2 sell ratings, 6 hold ratings and 6 buy ratings for the stock, resulting in a consensus rating of "Hold."
TypeToday30 Days Ago90 Days Ago180 Days Ago
RMD Consensus Rating: HoldBuyBuyHold
RMD Consensus Rating Score: 2.292.502.502.30
RMD Analyst Ratings: 2 Sell Rating(s)
6 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
4 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
5 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
RMD Consensus Price Target: $241.50$237.83$196.00$189.40
RMD Price Target Upside: 8.61% downside6.81% upside6.17% upside2.90% upside

ResMed (NYSE:RMD) Consensus Price Target History

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

ResMed (NYSE:RMD) Analyst Ratings History

DateBrokerageAnalyst NameActionRatingPrice TargetDetails
7/28/2021Jefferies Financial Group
UpgradeUnderperform ➝ Hold$170.00 ➝ $240.00
7/27/2021Royal Bank of Canada
Craig Wong-Pan
Boost Price TargetUnderperform$223.00 ➝ $238.00
7/26/2021JPMorgan Chase & Co.
DowngradeOverweight ➝ Neutral$245.00 ➝ $246.00
DowngradeBuy ➝ Neutral
UpgradeNeutral ➝ Outperform
6/21/2021Robert W. Baird
Initiated CoverageNeutral$240.00
6/21/2021Needham & Company LLC
Michael Matson
Boost Price TargetPositive ➝ Buy$229.00 ➝ $267.00
6/16/2021Bank of America
DowngradeNeutral ➝ Underperform$216.00 ➝ $221.00
Boost Price TargetOutperform$240.00 ➝ $270.00
UpgradeSell ➝ Outperform
11/2/2020UBS Group
UpgradeNeutral ➝ Buy$210.00
10/30/2020Credit Suisse Group
UpgradeNeutral ➝ Outperform
8/6/2020Morgan Stanley
Sean Laaman
DowngradeOverweight ➝ Equal Weight
8/6/2020The Goldman Sachs Group
DowngradeBuy ➝ Neutral
3/24/2020William Blair
Margaret Kaczor
Reiterated RatingBuy
Initiated CoverageSector Weight ➝ Sector Weight
3/20/2019Deutsche Bank Aktiengesellschaft
UpgradeHold ➝ Buy
1/28/2019BMO Capital Markets
Lower Price TargetOutperform ➝ Positive$120.00
(Data available from 7/28/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
This page was last updated on 7/28/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.